25 XP   0   0   10

Akari Therapeutics PLC
Buy, Hold or Sell?

Let's analyse Akari Therapeutics PLC together

PenkeI guess you are interested in Akari Therapeutics PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Akari Therapeutics PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Akari Therapeutics PLC

I send you an email if I find something interesting about Akari Therapeutics PLC.

Quick analysis of Akari Therapeutics PLC (30 sec.)










What can you expect buying and holding a share of Akari Therapeutics PLC? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.03
Expected worth in 1 year
$-0.37
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-0.40
Return On Investment
-21.7%

For what price can you sell your share?

Current Price per Share
$1.86
Expected price per share
$0 - $2.44
How sure are you?
50%

1. Valuation of Akari Therapeutics PLC (5 min.)




Live pricePrice per Share (EOD)

$1.86

Intrinsic Value Per Share

$-8.91 - $15.90

Total Value Per Share

$-8.88 - $15.93

2. Growth of Akari Therapeutics PLC (5 min.)




Is Akari Therapeutics PLC growing?

Current yearPrevious yearGrowGrow %
How rich?$1.7m$5.5m-$3.7m-210.2%

How much money is Akari Therapeutics PLC making?

Current yearPrevious yearGrowGrow %
Making money-$6.9m-$17.6m$10.6m152.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Akari Therapeutics PLC (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#833 / 1031

Most Revenue
#940 / 1031

Most Profit
#518 / 1031

Most Efficient
#395 / 1031

What can you expect buying and holding a share of Akari Therapeutics PLC? (5 min.)

Welcome investor! Akari Therapeutics PLC's management wants to use your money to grow the business. In return you get a share of Akari Therapeutics PLC.

What can you expect buying and holding a share of Akari Therapeutics PLC?

First you should know what it really means to hold a share of Akari Therapeutics PLC. And how you can make/lose money.

Speculation

The Price per Share of Akari Therapeutics PLC is $1.86. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Akari Therapeutics PLC.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Akari Therapeutics PLC, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.03. Based on the TTM, the Book Value Change Per Share is $-0.10 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.26 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Akari Therapeutics PLC.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.11-6.0%-0.11-6.0%-0.41-21.8%-0.63-33.8%-1.38-74.3%
Usd Book Value Change Per Share-0.10-5.4%-0.10-5.4%-0.26-14.1%-0.31-16.9%0.063.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.10-5.4%-0.10-5.4%-0.26-14.1%-0.31-16.9%0.063.3%
Usd Price Per Share0.47-0.47-1.50-1.43-3.92-
Price to Earnings Ratio-4.21--4.21--3.69--2.96--3.98-
Price-to-Total Gains Ratio-4.66--4.66--5.72--0.81--3.72-
Price to Book Ratio16.38-16.38-11.59-8.78-5.86-
Price-to-Total Gains Ratio-4.66--4.66--5.72--0.81--3.72-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.86
Number of shares537
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.10-0.31
Usd Total Gains Per Share-0.10-0.31
Gains per Quarter (537 shares)-54.09-168.95
Gains per Year (537 shares)-216.37-675.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-216-2260-676-686
20-433-4420-1352-1362
30-649-6580-2027-2038
40-865-8740-2703-2714
50-1082-10900-3379-3390
60-1298-13060-4055-4066
70-1515-15220-4731-4742
80-1731-17380-5406-5418
90-1947-19540-6082-6094
100-2164-21700-6758-6770

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.012.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.03.01.020.0%3.06.01.030.0%3.08.01.025.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.012.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.03.01.020.0%3.06.01.030.0%3.08.01.025.0%

Fundamentals of Akari Therapeutics PLC

About Akari Therapeutics PLC

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Fundamental data was last updated by Penke on 2024-03-20 09:15:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Akari Therapeutics PLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Akari Therapeutics PLC earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Akari Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM--205.8%+205.8%
YOY--262.1%+262.1%
5Y--455.6%+455.6%
10Y--589.0%+589.0%
1.1.2. Return on Assets

Shows how efficient Akari Therapeutics PLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • -50.4% Return on Assets means that Akari Therapeutics PLC generated $-0.50 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Akari Therapeutics PLC:

  • The MRQ is -50.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -50.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-50.4%TTM-50.4%0.0%
TTM-50.4%YOY-151.2%+100.7%
TTM-50.4%5Y-121.8%+71.4%
5Y-121.8%10Y-100.4%-21.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-50.4%-12.5%-37.9%
TTM-50.4%-12.2%-38.2%
YOY-151.2%-11.2%-140.0%
5Y-121.8%-13.4%-108.4%
10Y-100.4%-14.7%-85.7%
1.1.3. Return on Equity

Shows how efficient Akari Therapeutics PLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • -389.3% Return on Equity means Akari Therapeutics PLC generated $-3.89 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Akari Therapeutics PLC:

  • The MRQ is -389.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -389.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-389.3%TTM-389.3%0.0%
TTM-389.3%YOY-317.0%-72.4%
TTM-389.3%5Y-311.1%-78.2%
5Y-311.1%10Y-210.3%-100.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-389.3%-15.8%-373.5%
TTM-389.3%-15.7%-373.6%
YOY-317.0%-13.9%-303.1%
5Y-311.1%-18.3%-292.8%
10Y-210.3%-19.2%-191.1%

1.2. Operating Efficiency of Akari Therapeutics PLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Akari Therapeutics PLC is operating .

  • Measures how much profit Akari Therapeutics PLC makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Akari Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.1%+299.1%
TTM--210.1%+210.1%
YOY--279.7%+279.7%
5Y--459.9%+459.9%
10Y--596.9%+596.9%
1.2.2. Operating Ratio

Measures how efficient Akari Therapeutics PLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.861-2.861
TTM-3.193-3.193
YOY-3.615-3.615
5Y-5.560-5.560
10Y-7.396-7.396

1.3. Liquidity of Akari Therapeutics PLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Akari Therapeutics PLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.15 means the company has $1.15 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 1.147. The company is just able to pay all its short-term debts.
  • The TTM is 1.147. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.147TTM1.1470.000
TTM1.147YOY1.908-0.760
TTM1.1475Y2.299-1.152
5Y2.29910Y3.298-0.998
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1473.986-2.839
TTM1.1474.440-3.293
YOY1.9085.552-3.644
5Y2.2996.158-3.859
10Y3.2986.492-3.194
1.3.2. Quick Ratio

Measures if Akari Therapeutics PLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • A Quick Ratio of 1.35 means the company can pay off $1.35 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 1.345. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.345. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.345TTM1.3450.000
TTM1.345YOY1.536-0.191
TTM1.3455Y2.480-1.135
5Y2.48010Y4.251-1.771
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3453.638-2.293
TTM1.3454.168-2.823
YOY1.5365.515-3.979
5Y2.4806.012-3.532
10Y4.2516.209-1.958

1.4. Solvency of Akari Therapeutics PLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Akari Therapeutics PLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Akari Therapeutics PLC to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.87 means that Akari Therapeutics PLC assets are financed with 87.1% credit (debt) and the remaining percentage (100% - 87.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 0.871. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.871. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.871TTM0.8710.000
TTM0.871YOY0.523+0.347
TTM0.8715Y0.526+0.344
5Y0.52610Y0.401+0.125
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8710.335+0.536
TTM0.8710.330+0.541
YOY0.5230.267+0.256
5Y0.5260.367+0.159
10Y0.4010.378+0.023
1.4.2. Debt to Equity Ratio

Measures if Akari Therapeutics PLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • A Debt to Equity ratio of 672.4% means that company has $6.72 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Akari Therapeutics PLC:

  • The MRQ is 6.724. The company is unable to pay all its debts with equity. -1
  • The TTM is 6.724. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ6.724TTM6.7240.000
TTM6.724YOY1.097+5.627
TTM6.7245Y2.077+4.647
5Y2.07710Y1.230+0.847
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.7240.376+6.348
TTM6.7240.398+6.326
YOY1.0970.334+0.763
5Y2.0770.429+1.648
10Y1.2300.476+0.754

2. Market Valuation of Akari Therapeutics PLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Akari Therapeutics PLC generates.

  • Above 15 is considered overpriced but always compare Akari Therapeutics PLC to the Biotechnology industry mean.
  • A PE ratio of -4.21 means the investor is paying $-4.21 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Akari Therapeutics PLC:

  • The EOD is -16.656. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.208. Based on the earnings, the company is expensive. -2
  • The TTM is -4.208. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-16.656MRQ-4.208-12.448
MRQ-4.208TTM-4.2080.000
TTM-4.208YOY-3.695-0.513
TTM-4.2085Y-2.962-1.246
5Y-2.96210Y-3.978+1.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-16.656-2.643-14.013
MRQ-4.208-2.418-1.790
TTM-4.208-2.742-1.466
YOY-3.695-4.123+0.428
5Y-2.962-6.257+3.295
10Y-3.978-6.478+2.500
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Akari Therapeutics PLC:

  • The EOD is -5.400. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.364. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.364. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.400MRQ-1.364-4.036
MRQ-1.364TTM-1.3640.000
TTM-1.364YOY-3.416+2.052
TTM-1.3645Y-2.411+1.046
5Y-2.41110Y-4.627+2.217
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.400-3.244-2.156
MRQ-1.364-2.939+1.575
TTM-1.364-3.478+2.114
YOY-3.416-5.592+2.176
5Y-2.411-8.473+6.062
10Y-4.627-8.881+4.254
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Akari Therapeutics PLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 16.38 means the investor is paying $16.38 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Akari Therapeutics PLC:

  • The EOD is 64.849. Based on the equity, the company is expensive. -2
  • The MRQ is 16.383. Based on the equity, the company is expensive. -2
  • The TTM is 16.383. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD64.849MRQ16.383+48.466
MRQ16.383TTM16.3830.000
TTM16.383YOY11.591+4.792
TTM16.3835Y8.784+7.599
5Y8.78410Y5.857+2.928
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD64.8492.124+62.725
MRQ16.3832.041+14.342
TTM16.3832.118+14.265
YOY11.5912.915+8.676
5Y8.7843.682+5.102
10Y5.8574.114+1.743
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Akari Therapeutics PLC.

3.1. Institutions holding Akari Therapeutics PLC

Institutions are holding 1.937% of the shares of Akari Therapeutics PLC.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Omnia Family Wealth, LLC1.550.1401876282851148.2281
2023-12-31HPM Partners LLC0.41820.00022364300
2023-12-31Renaissance Technologies Corp0.18160.000110269-7200-41.2159
2023-12-31Bank of America Corp0.0027015000
2023-12-31Truvestments Capital LLC0.00090.00015000
2023-12-31Morgan Stanley - Brokerage Accounts0.00010880
2023-12-31Tower Research Capital LLC0.00010770
2023-09-30WSFS CAPITAL MANAGEMENT, LLC000-5000-100
2023-09-30Sabby Management LLC000-369607-100
2023-09-30UBS Group AG000-1223-100
2023-09-30Millennium Management LLC000-6702-100
2023-12-31Cornerstone Planning Group LLC000-5-100
2023-09-30Hikari Power Ltd000-6541-100
2023-09-30Geode Capital Management, LLC000-1513-100
2023-09-30LPL Financial Corp000-6723-100
2023-12-31NEA Management Company, LLC000-22608-100
2023-09-30Virtu Financial LLC000-822-100
2023-09-30TWO SIGMA SECURITIES, LLC000-881-100
Total 2.15360.1405121755-400299-328.8%

3.2. Funds holding Akari Therapeutics PLC

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29LUX IM Global Medtech HX0.10810.0063611400
2024-01-31Fidelity Nasdaq Composite Index0.02670151200
Total 0.13480.0063762600.0%

3.3. Insider Transactions

Insiders are holding 21.5% of the shares of Akari Therapeutics PLC.

DateOwnerTypeAmountPricePost Transaction AmountLink
2015-09-18Mark S CohenBUY10556000.191055600
2014-04-15Sabby Management, LlcBUY201005.03
2014-04-11Sabby Management, LlcBUY25755.35
2014-04-08Sabby Management, LlcBUY684045.59
2014-04-02Sabby Management, LlcBUY282076.22
2014-03-27Sabby Management, LlcBUY162036.66
2014-03-24Sabby Management, LlcBUY111006.83

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Akari Therapeutics PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.101-0.1010%-0.262+160%-0.315+212%0.062-262%
Book Value Per Share--0.0290.0290%0.129-78%0.464-94%1.442-98%
Current Ratio--1.1471.1470%1.908-40%2.299-50%3.298-65%
Debt To Asset Ratio--0.8710.8710%0.523+66%0.526+65%0.401+117%
Debt To Equity Ratio--6.7246.7240%1.097+513%2.077+224%1.230+447%
Dividend Per Share----0%-0%-0%-0%
Eps---0.112-0.1120%-0.406+264%-0.628+462%-1.382+1138%
Free Cash Flow Per Share---0.344-0.3440%-0.439+27%-0.880+156%-1.227+256%
Free Cash Flow To Equity Per Share--0.0610.0610%-0.106+275%-0.216+457%0.532-89%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--15.903--------
Intrinsic Value_10Y_min---8.908--------
Intrinsic Value_1Y_max---0.002--------
Intrinsic Value_1Y_min---1.154--------
Intrinsic Value_3Y_max--1.211--------
Intrinsic Value_3Y_min---3.262--------
Intrinsic Value_5Y_max--3.889--------
Intrinsic Value_5Y_min---5.127--------
Market Cap10515417.000-179%29338029.81829338029.8180%64381690.500-54%42209415.110-30%50668178.663-42%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio64.849+75%16.38316.3830%11.591+41%8.784+87%5.857+180%
Pe Ratio-16.656-296%-4.208-4.2080%-3.695-12%-2.962-30%-3.978-5%
Price Per Share1.860+75%0.4700.4700%1.500-69%1.428-67%3.923-88%
Price To Free Cash Flow Ratio-5.400-296%-1.364-1.3640%-3.416+150%-2.411+77%-4.627+239%
Price To Total Gains Ratio-18.465-296%-4.665-4.6650%-5.718+23%-0.808-83%-3.717-20%
Quick Ratio--1.3451.3450%1.536-12%2.480-46%4.251-68%
Return On Assets---0.504-0.5040%-1.512+200%-1.218+142%-1.004+99%
Return On Equity---3.893-3.8930%-3.170-19%-3.111-20%-2.103-46%
Total Gains Per Share---0.101-0.1010%-0.262+160%-0.315+212%0.062-262%
Usd Book Value--1790746.0001790746.0000%5554582.000-68%8707059.800-79%15700334.500-89%
Usd Book Value Change Per Share---0.101-0.1010%-0.262+160%-0.315+212%0.062-262%
Usd Book Value Per Share--0.0290.0290%0.129-78%0.464-94%1.442-98%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.112-0.1120%-0.406+264%-0.628+462%-1.382+1138%
Usd Free Cash Flow---21504522.000-21504522.0000%-18846528.000-12%-20238928.800-6%-17745366.600-17%
Usd Free Cash Flow Per Share---0.344-0.3440%-0.439+27%-0.880+156%-1.227+256%
Usd Free Cash Flow To Equity Per Share--0.0610.0610%-0.106+275%-0.216+457%0.532-89%
Usd Market Cap10515417.000-179%29338029.81829338029.8180%64381690.500-54%42209415.110-30%50668178.663-42%
Usd Price Per Share1.860+75%0.4700.4700%1.500-69%1.428-67%3.923-88%
Usd Profit---6972252.000-6972252.0000%-17606856.000+153%-18372820.000+164%-19651462.100+182%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.101-0.1010%-0.262+160%-0.315+212%0.062-262%
 EOD+3 -5MRQTTM+0 -0YOY+15 -145Y+14 -1510Y+8 -21

4.2. Fundamental Score

Let's check the fundamental score of Akari Therapeutics PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-16.656
Price to Book Ratio (EOD)Between0-164.849
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.345
Current Ratio (MRQ)Greater than11.147
Debt to Asset Ratio (MRQ)Less than10.871
Debt to Equity Ratio (MRQ)Less than16.724
Return on Equity (MRQ)Greater than0.15-3.893
Return on Assets (MRQ)Greater than0.05-0.504
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Akari Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.757
Ma 20Greater thanMa 502.064
Ma 50Greater thanMa 1002.338
Ma 100Greater thanMa 2002.727
OpenGreater thanClose1.850
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Interest Expense  82185267-622055210-5,550-5,340



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets13,832
Total Liabilities12,041
Total Stockholder Equity1,791
 As reported
Total Liabilities 12,041
Total Stockholder Equity+ 1,791
Total Assets = 13,832

Assets

Total Assets13,832
Total Current Assets13,815
Long-term Assets17
Total Current Assets
Cash And Cash Equivalents 13,250
Net Receivables 2,951
Inventory -2,486
Other Current Assets 100
Total Current Assets  (as reported)13,815
Total Current Assets  (calculated)13,815
+/-0
Long-term Assets
Property Plant Equipment 172
Intangible Assets 17
Long-term Assets  (as reported)17
Long-term Assets  (calculated)189
+/- 172

Liabilities & Shareholders' Equity

Total Current Liabilities12,041
Long-term Liabilities947
Total Stockholder Equity1,791
Total Current Liabilities
Accounts payable 947
Other Current Liabilities 11,094
Total Current Liabilities  (as reported)12,041
Total Current Liabilities  (calculated)12,041
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)947
Long-term Liabilities  (calculated)0
+/- 947
Total Stockholder Equity
Common Stock744
Retained Earnings -217,453
Accumulated Other Comprehensive Income -771
Other Stockholders Equity 219,270
Total Stockholder Equity (as reported)1,791
Total Stockholder Equity (calculated)1,791
+/-0
Other
Capital Stock744
Cash and Short Term Investments 13,250
Common Stock Shares Outstanding 62,435
Liabilities and Stockholders Equity 13,832
Net Debt -13,250
Net Invested Capital 1,791
Net Working Capital 1,774



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
> Total Assets 
0
27
1,120
7,832
6,480
69,894
45,874
29,050
29,050
10,307
17,595
11,648
13,832
13,83211,64817,59510,30729,05029,05045,87469,8946,4807,8321,120270
   > Total Current Assets 
0
27
1,118
7,832
6,431
69,658
45,634
28,813
28,813
10,272
17,568
11,625
13,815
13,81511,62517,56810,27228,81328,81345,63469,6586,4317,8321,118270
       Cash And Cash Equivalents 
0
6
1,104
7,657
6,216
68,920
34,099
28,107
28,107
5,732
14,056
9,361
13,250
13,2509,36114,0565,73228,10728,10734,09968,9206,2167,6571,10460
       Short-term Investments 
0
0
0
10,000
0
0
10,022
0
0
0
0
0
0
00000010,0220010,000000
       Net Receivables 
0
21
14
175
73
10
0
0
10,431
4,540
3,512
0
2,951
2,95103,5124,54010,43100107317514210
       Other Current Assets 
0
0
0
0
142
730
1,510
706
706
1,035
522
90
100
100905221,0357067061,5107301420000
   > Long-term Assets 
0
0
2
0
49
235
240
237
237
35
27
23
17
17232735237237240235490200
       Property Plant Equipment 
0
0
2
0
49
41
58
56
56
5
172
165
172
172165172556565841490200
       Intangible Assets 
0
0
0
0
59
52
39
39
39
30
27
23
17
1723273039393952590000
       Other Assets 
0
0
0
0
0
142
142
142
522
0
0
0
0
000052214214214200000
> Total Liabilities 
0
2,512
4,480
2,018
1,627
21,174
11,771
9,071
9,071
6,471
5,220
6,093
12,041
12,0416,0935,2206,4719,0719,07111,77121,1741,6272,0184,4802,5120
   > Total Current Liabilities 
0
2,236
3,850
1,231
1,359
21,125
11,715
9,023
9,023
5,456
5,220
6,093
12,041
12,0416,0935,2205,4569,0239,02311,71521,1251,3591,2313,8502,2360
       Short-term Debt 
0
0
898
1,000
534
0
0
0
0
0
0
0
0
000000005341,00089800
       Short Long Term Debt 
0
0
0
1,000
534
0
0
0
0
0
0
0
0
000000005341,000000
       Accounts payable 
0
1,379
1,697
652
1,007
4,321
2,214
1,971
1,971
1,228
3,380
1,789
947
9471,7893,3801,2281,9711,9712,2144,3211,0076521,6971,3790
       Other Current Liabilities 
0
857
1,255
579
352
16,804
9,500
7,052
7,052
4,228
1,840
4,305
11,094
11,0944,3051,8404,2287,0527,0529,50016,8043525791,2558570
   > Long-term Liabilities 
0
276
630
787
268
49
56
48
48
1,015
3,380
4,305
947
9474,3053,3801,015484856492687876302760
       Other Liabilities 
0
0
0
0
49
49
56
48
0
0
0
0
0
00000485649490000
> Total Stockholder Equity
0
-2,485
-3,360
5,814
4,853
48,720
34,103
19,979
19,979
3,836
12,375
5,555
1,791
1,7915,55512,3753,83619,97919,97934,10348,7204,8535,814-3,360-2,4850
   Common Stock
0
225
245
675
927
18,341
18,341
22,928
22,928
31,987
385
476
744
74447638531,98722,92822,92818,34118,3419276752452250
   Retained Earnings Total Equity0000000000000
   Accumulated Other Comprehensive Income 
0
-9
-11
-10
-18
156
-280
-236
-236
-12,242
-10,941
-541
-771
-771-541-10,941-12,242-236-236-280156-18-10-11-90
   Capital Surplus 
0
0
0
0
0
0
0
0
106,616
110,499
0
0
0
000110,499106,61600000000
   Treasury Stock0000000000000
   Other Stockholders Equity 
0
9,920
13,328
25,691
34,134
87,023
90,983
104,800
104,800
122,327
179,558
205,325
219,270
219,270205,325179,558122,327104,800104,80090,98387,02334,13425,69113,3289,9200



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-4
Gross Profit-4-4
 
Operating Income (+$)
Gross Profit-4
Operating Expense-23,891
Operating Income-23,088-23,895
 
Operating Expense (+$)
Research Development9,561
Selling General Administrative13,527
Selling And Marketing Expenses0
Operating Expense23,89123,088
 
Net Interest Income (+$)
Interest Income46
Interest Expense--5,340
Other Finance Cost-5,340
Net Interest Income46
 
Pretax Income (+$)
Operating Income-23,088
Net Interest Income46
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-17,748-28,428
EBIT - interestExpense = -17,748
-17,748
-12,312
Interest Expense-5,340
Earnings Before Interest and Taxes (EBIT)-23,088-23,088
Earnings Before Interest and Taxes (EBITDA)-28,520
 
After tax Income (+$)
Income Before Tax-17,748
Tax Provision--2,472
Net Income From Continuing Ops-17,748-15,276
Net Income-6,972
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses23,088
Total Other Income/Expenses Net5,340-46
 

Technical Analysis of Akari Therapeutics PLC
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Akari Therapeutics PLC. The general trend of Akari Therapeutics PLC is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Akari Therapeutics PLC's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Akari Therapeutics PLC.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.1 < 2.4 < 2.44.

The bearish price targets are: .

Tweet this
Akari Therapeutics PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Akari Therapeutics PLC. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Akari Therapeutics PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Akari Therapeutics PLC. The current macd is -0.14673457.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Akari Therapeutics PLC price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Akari Therapeutics PLC. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Akari Therapeutics PLC price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Akari Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) ChartAkari Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Akari Therapeutics PLC. The current adx is 46.15.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Akari Therapeutics PLC shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Akari Therapeutics PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Akari Therapeutics PLC. The current sar is 2.00587205.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Akari Therapeutics PLC Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Akari Therapeutics PLC. The current rsi is 31.76. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Akari Therapeutics PLC Daily Relative Strength Index (RSI) ChartAkari Therapeutics PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Akari Therapeutics PLC. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Akari Therapeutics PLC price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Akari Therapeutics PLC Daily Stochastic Oscillator ChartAkari Therapeutics PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Akari Therapeutics PLC. The current cci is -98.29436168.

Akari Therapeutics PLC Daily Commodity Channel Index (CCI) ChartAkari Therapeutics PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Akari Therapeutics PLC. The current cmo is -38.75226334.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Akari Therapeutics PLC Daily Chande Momentum Oscillator (CMO) ChartAkari Therapeutics PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Akari Therapeutics PLC. The current willr is -68.25396825.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Akari Therapeutics PLC is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Akari Therapeutics PLC Daily Williams %R ChartAkari Therapeutics PLC Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Akari Therapeutics PLC.

Akari Therapeutics PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Akari Therapeutics PLC. The current atr is 0.1498351.

Akari Therapeutics PLC Daily Average True Range (ATR) ChartAkari Therapeutics PLC Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Akari Therapeutics PLC. The current obv is 49,760.

Akari Therapeutics PLC Daily On-Balance Volume (OBV) ChartAkari Therapeutics PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Akari Therapeutics PLC. The current mfi is 40.93.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Akari Therapeutics PLC Daily Money Flow Index (MFI) ChartAkari Therapeutics PLC Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Akari Therapeutics PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-16STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Akari Therapeutics PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Akari Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.757
Ma 20Greater thanMa 502.064
Ma 50Greater thanMa 1002.338
Ma 100Greater thanMa 2002.727
OpenGreater thanClose1.850
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Akari Therapeutics PLC with someone you think should read this too:
  • Are you bullish or bearish on Akari Therapeutics PLC? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Akari Therapeutics PLC? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Akari Therapeutics PLC

I send you an email if I find something interesting about Akari Therapeutics PLC.


Comments

How you think about this?

Leave a comment

Stay informed about Akari Therapeutics PLC.

Receive notifications about Akari Therapeutics PLC in your mailbox!